Do you want to read an article? Please log in or register.
Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction
Atrial Fibrillation
Related content
Atrial Fibrillation
Treating Specialty and Outcomes in Newly Diagnosed Atrial Fibrillation: From the TREAT-AF Study
J Am Coll Cardiol.
Perino AC, Fan J, Schmitt SK, Askari M, Kaiser DW, Deshmukh A, Heidenreich PA, Swan C, Narayan SM, Wang PJ, Turakhia MP
doi: 10.1016/j.jacc.2017.04.054.
Atrial Fibrillation
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial
Eur Heart J.
Boriani G, Ruff CT, Kuder JF, Shi M, Lanz HJ, Rutman H, Mercuri MF, Antman EM, Braunwald E, Giugliano RP
doi: 10.1093/eurheartj/ehy861.
Atrial FibrillationThrombosis and StrokeTherapy and Intervention
Long-term Thromboembolic Risk in Patients With Postoperative Atrial Fibrillation After Coronary Artery Bypass Graft Surgery and Patients With Nonvalvular Atrial Fibrillation
JAMA Cardiol.
Butt JH, Xian Y, Peterson ED, Olsen PS, Rørth R, Gundlund A, Olesen JB, Gislason GH, Torp-Pedersen C, Køber L, Fosbøl EL
doi: 10.1001/jamacardio.
COMMENTED
Atrial Fibrillation
Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial
★ 3
Recommended and commented by
Prof. Dr Sacha P. Salzberg, Faculty Member
doi: 10.1001/jama.2019.21187.
Atrial FibrillationTherapy and Intervention
Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
Circ Cardiovasc Interv.
Kerneis M, Yee MK, Mehran R, Nafee T, Bode C, Halperin JL, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Fox KAA, Gibson CM
doi: 10.1161/CIRCINTERVENTIONS.
Atrial FibrillationThrombosis and Stroke
Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients
Thromb Haemost.
Li X, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Lip GY
doi: 10.1160/
Atrial FibrillationTherapy and Intervention
Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI
JACC Cardiovasc Interv.
Hohnloser SH, Steg PG, Oldgren J, Nickenig G, Kiss RG, Ongen Z, Navarro Estrada JL, Oude Ophuis T, Lip GYH, Nordaby M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP, RE-DUAL PCI Steering Committee and Investigators.
doi: 10.1016/j.jcin.2019.05.050.
Atrial Fibrillation
Relationship of Preexisting Cardiovascular Comorbidities to Newly Diagnosed Atrial Fibrillation After Ischemic Stroke
Bisson A, Clementy N, Bodin A, Angoulvant D, Babuty D, Lip GYH, Fauchier L
doi: 10.1161/
Atrial FibrillationHeart Failure
Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure
ESC Heart Fail.
Martinez BK, Bunz TJ, Eriksson D, Meinecke AK, Sood NA, Coleman CI
doi: 10.1002/ehf2.12365.